Identification of potential pathways and biomarkers linked to progression in ALS
Open Access
- 19 December 2022
- journal article
- research article
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 10 (2) , 150-165
Abstract
Objective: To identify potential diagnostic and prognostic biomarkers for clinical management and clinical trials in amyotrophic lateral sclerosis.Methods: We analysed proteomics data of ALS patient‐induced pluripotent stem cell‐derived motor neurons available through the AnswerALS consortium. After stratifying patients using clinical ALSFRS‐R and ALS‐CBS scales, we identified differentially expressed proteins indicative of ALS disease severity and progression rate as candidate ALS‐related and prognostic biomarkers. Pathway analysis for identified proteins was performed using STITCH. Protein sets were correlated with the effects of drugs using the Connectivity Map tool to identify compounds likely to affect similar pathways. RNAi screening was performed in a Drosophila TDP‐43 ALS model to validate pathological relevance. A statistical classification machine learning model was constructed using ridge regression that uses proteomics data to differentiate ALS patients from controls.Results: We identified 76, 21, 71 and 1 candidate ALS‐related biomarkers and 22, 41, 27 and 64 candidate prognostic biomarkers from patients stratified by ALSFRS‐R baseline, ALSFRS‐R progression slope, ALS‐CBS baseline and ALS‐CBS progression slope, respectively. Nineteen proteins enhanced or suppressed pathogenic eye phenotypes in the ALS fly model. Nutraceuticals, dopamine pathway modulators, statins, anti‐inflammatories and antimicrobials were predicted starting points for drug repurposing using the connectivity map tool. Ten diagnostic biomarker proteins were predicted by machine learning to identify ALS patients with high accuracy and sensitivity.Interpretation: This study showcases the powerful approach of iPSC‐motor neuron proteomics combined with machine learning and biological confirmation in the prediction of novel mechanisms and diagnostic and predictive biomarkers in ALS.Keywords
Funding Information
- Agency for Science, Technology and Research
- National Institutes of Health (R01AG059871)
This publication has 52 references indexed in Scilit:
- Curcumin and neurodegenerative diseasesBioFactors, 2013
- Applications of Connectivity Map in drug discovery and developmentDrug Discovery Today, 2012
- A systematic review of behavioural changes in motor neuron diseaseAmyotrophic Lateral Sclerosis, 2012
- Proteomic Analysis of Hippocampal Dentate Granule Cells in Frontotemporal Lobar Degeneration: Application of Laser Capture TechnologyFrontiers in Neurology, 2011
- Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALSNature, 2010
- TDP-43 Mediates Degeneration in a NovelDrosophilaModel of Disease Caused by Mutations in VCP/p97The Journal of Neuroscience, 2010
- Detecting frontotemporal dysfunction in ALS: Utility of the ALS Cognitive Behavioral Screen (ALS-CBS™)Amyotrophic Lateral Sclerosis, 2009
- STITCH: interaction networks of chemicals and proteinsNucleic Acids Research, 2007
- The Connectivity Map: a new tool for biomedical researchNature Reviews Cancer, 2007
- The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and DiseaseScience, 2006